From Winston & Strawn, by Neely Agin and Hannah Gallagher, writing for AHLA (Subscription):
- FTC and DOJ have increased regulatory scrutiny on the health care industry, particularly private equity investors.
- FTC Chairwoman Lina Khan has expressed concern over “roll-up” or consolidation strategies in the health care industry, citing potential negative effects on quality of care and costs for patients.
- In its recent complaint against Welsh Carson and USAP, the FTC alleges a “multi-year anticompetitive scheme” to consolidate anesthesiology practices in Texas and drive up prices.
- The complaint also includes claims against Welsh Carson, the private equity firm, and not just the portfolio company.
- This lawsuit serves as a reminder to private equity firms to carefully consider potential antitrust risks in their investments and post-consummation behavior.